Evidence map›Paper›PMID 38089563›Full record

ArticleMultiple sclerosis journal - experimental, translational and clinical

Humoral immune response after Ad26.COV2.S vaccination in patients with multiple sclerosis treated with natalizumab.

Mark Gudesblatt, Myassar Zarif, Barbara Bumstead, Marijean Buhse, Olivia Kaczmarek, Hanyue Li, Zhaonan Sun, Nicole Scott, Jason P Mendoza, Robin L Avila

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mark GudesblattNYU Langone South Shore Neurologic Associates, PC, Patchogue, NY, USA.
Myassar ZarifNYU Langone South Shore Neurologic Associates, PC, Patchogue, NY, USA.
Barbara BumsteadNYU Langone South Shore Neurologic Associates, PC, Patchogue, NY, USA.
Marijean BuhseNYU Langone South Shore Neurologic Associates, PC, Patchogue, NY, USA.
Olivia KaczmarekNYU Langone South Shore Neurologic Associates, PC, Patchogue, NY, USA.
Hanyue LiBiogen, Cambridge, MA, USA.
Zhaonan SunBiogen, Cambridge, MA, USA.
Nicole ScottBiogen, Cambridge, MA, USA.
Jason P MendozaBiogen, Cambridge, MA, USA.
Robin L AvilaBiogen, Cambridge, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The immunomodulatory effects of disease-modifying therapies for multiple sclerosis might affect the immune response to vaccines for severe acute respiratory syndrome coronavirus 2. We analyzed the severe acute respiratory syndrome coronavirus 2-specific antibody response and lymphocyte profile before and after Ad26.COV2.S (Johnson & Johnson) vaccination in natalizumab-treated patients with multiple sclerosis. There was a 72-fold increase in mean anti-severe acute respiratory syndrome coronavirus 2 spike immunoglobulin G levels 4 weeks after vaccination and a 137-fold increase after 6 months. Other immune signals were within normal ranges. Natalizumab-treated patients with multiple sclerosis had a robust immune response to Ad26.COV2.S vaccine, and other immune signals were not significantly affected.

Indexed as

COVID-19Multiple sclerosisnatalizumabvaccine

Identifiers

PMID38089563
PMCPMC10714887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.